Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of AT-587 in Healthy Adult Participants
NCT07728487Phase 1Recruiting
- Sponsor
- Atea Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AT-587 in hepatitis E (HEV) (14 arms), sponsored by Atea Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events. Started Jul 2026; status: recruiting.
02
Drugs
AT-587
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT07728487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07728487.